ESR2 and colorectal carcinoma: Decreased CRC risk was associated with duration of HRT use specifically in ERβ-positive patients (OR for each 5 years interval: 0.87, 95% CI: 0.77–0.99) but not in ERβ-negative patients (OR: 1.02, 95% CI: 0.91–1.15) (44).